PFS, Response Rate Suitable Surrogates for Overall Survival in RCTs of Soft Tissue Sarcoma

Share this content:
Progression-free survival and response rate appeared to be suitable surrogates for overall survival in advanced soft tissue sarcoma.
Progression-free survival and response rate appeared to be suitable surrogates for overall survival in advanced soft tissue sarcoma.

Progression-free survival and response rate appeared to be suitable surrogates for overall survival in advanced soft tissue sarcoma, according to a study published in the Journal of Clinical Oncology.1

It was also found that there was a poor correlation between 3- and 6-month progression-free survival and overall survival. Investigators cautioned against the use of these as primary endpoints in soft tissue sarcoma trials.

The rationale for the study was that randomized controlled trials in soft tissue sarcoma have used varying endpoints and the surrogacy of the endpoints was unknown.

In this systematic review of systemic therapy of randomized controlled trials in soft tissue sarcoma, surrogacy between intermediate endpoints and overall survival was explored using weighted liner regression for the hazard ratio for overall survival with the hazard ratio for progression-free survival or the odds ratio for response rate, 3- and 6-month progression-free survival. Investigators also evaluated the quality of reporting for efficacy and toxicity.

A total of 53 randomized controlled trials published between 1974 and 2014 were analyzed. A total of 9762 patients were included.

Results showed that there were significant correlations between progression-free survival and overall survival (R = 0.61) and between response rate and overall survival (R = 0.51). Nonsignificant correlations were observed between overall survival and 3- or 6-month progression-free survival.

Researchers found that in 14% of trials, the primary endpoint was not met yet the study was reported as being positive.

RELATED: Panobinostat Plus Epirubicin May Be Active in Refractory Sarcoma

In regard to safety, toxicity was comprehensively reported in 47% of randomized controlled trials, and 14% inadequately reported toxicity.

The authors concluded that “the quality of toxicity reporting and interpretations of results is suboptimal.”

Reference

  1. Zer A, Prince RM, Amir, E, Razak AA. Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: endpoint selection, surrogacy, and quality of reporting [published online ahead of print March 7, 2016].  J Clin Oncol. doi: 10.1200/JCO.2015.64.3437.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters